JCI Insight

Inhibiting a small RNA slowed lung scarring in aged mice

In 18-month-old mice, weekly injections starting 14 days after lung injury preserved lung blood vessels and limited scarring progression by day 30.

Paper by Giuseppe Muscato, Benjamin B. Roos, Sharonda Harris, +10 more authorsNunzia Caporarello · University of Catania · Loyola University Chicago

Our read

Mechanisms
Studied:
Experiments in aged male and female mice, until day 30, against control-treated mice
What changed:
Blocking the small RNA reduced lung scarring progression in aged mice compared with control treatment
The catch:
Lungs were examined on day 30, limiting assessment of longer-term scarring
In the record:
One of 7 papers on MIR205 on record: 1 with results in people.
Why it’s aging research:
It studies organisms or tissues that aged naturally.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

Experiments in 18-month-old male and female mice tested inhibition of miR-205-5p, a small RNA that regulates gene activity. Researchers induced lung scarring with bleomycin. They gave the inhibitor at 10 milligrams per kilogram or a control intravenously once weekly from day 14, and examined lungs on day 30. Inhibition preserved the lung blood vessel network and reduced scarring progression.

Human lung samples came from seven transplant patients with idiopathic pulmonary fibrosis, an aging-related lung-scarring disease, and four healthy donors. The patients were five males and two females; the donors were three males and one female. The RNA was elevated in blood vessel lining cells from fibrotic lungs. In cells grown in the lab from patients’ lungs, inhibiting it reduced senescence, a state in which cells stop dividing. It also limited these cells’ ability to activate fibroblasts, cells involved in scarring.

Why it matters

The authors highlight inhibition of this RNA as a potential intervention for idiopathic pulmonary fibrosis, a fatal disease linked to aging.

Caveats

The human comparison was observational and used transplant lungs and deceased-donor controls; it cannot establish causation in people. The inhibitor was tested in cultured cells and mice, not patients.

Comments

Be the first to comment.